LYDIA ROY, MD
Centre Hospitalo-Universitaire Henri Mondor, Service d'Hematologie Clinique · Hôpital Henri Mondor - Créteil - France · France Intergroupe Syndromes Myéloprolifératifs
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name LYDIA ROY, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03831776 · Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisSt. Olavs Hospital · completed · Chronic Myeloid Leukemia · principal investigator
- N/ANCT03208803 · Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in MyelofibrosisCentre Hospitalier Annecy Genevois · completed · Myelofibrosis; Anemia · study director
- Ph2/Ph3NCT02962388 · The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineFrench Innovative Leukemia Organisation · terminated · Essential Thrombocythemia · principal investigator
- Ph2NCT01872442 · Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhasePoitiers University Hospital · completed · Chronic Phase of Chronic Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.